CurveBeam AI

QUARTERLY 4C CONFERENCE CALL

October 2023

DISCLAIMER

Introduction
THIS DOCUMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA OR TO ANY RESIDENT THEREOF, OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. THIS DOCUMENT IS NOT AN OFFER OR INVITATION TO BUY OR SELL SECURITIES.

This presentation has been prepared by CurveBeam AI Limited (ACN 140 706 618) (**CurveBeam** or the **Company**) and contains summary information about CurveBeam and the business conducted by it as at 24 October 2023. The information in this presentation is for informational purposes only, does not purport to be complete and is not a prospectus, product disclosure statement or other disclosure document for the purposes of Chapter 6D or Part 7.9 of the Corporations Act 2001 (Cth) (**Act**) or other offer document under Australian law or the law of any other jurisdiction.

The distribution of this document outside of Australia may be restricted by law and any such restrictions should be observed. This document may not be distributed or released to any person in the United States.
As further detailed below, none of CurveBeam, nor its advisers (**Advisers**) nor their respective affiliates, related bodies corporate (as defined in the Act) or security holders and their respective directors, officers, employees, partners, representatives, consultants, agents or advisers (each a **Limited Party** and together, the **Limited Parties**) guarantees or make any representation or warranty to, or takes responsibility for, the accuracy, reliability or completeness of the information contained in this presentation, to the recipient of this document (you or the Recipient), and nothing contained in this document is, or may be relied upon as, a promise or representation, whether as to the past or future. To the maximum extent permitted by law, each Limited Party disclaims any liability for any loss arising from the use of information including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions or matters, express or implied, contained in, arising out of or derived from, or for omissions from, this presentation.

Not an offer or financial product advice
The information contained in this presentation is for informational purposes only and should not be considered, and does not contain or purport to contain, an offer, invitation, solicitation or recommendation with respect the purchase or sale of any securities in CurveBeam nor does it constitute legal, taxation, financial product or investment advice. The general information in this presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. Recipients of the presentation must undertake their own independent investigations, consideration and evaluation. By accepting this presentation, a Recipient agrees that if it proceeds further with its investigations, consideration or evaluation of investing in CurveBeam it will not in any way rely upon this document. Neither this presentation nor any of its contents will form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in any transaction nor is it intended to be used as the basis for making an investment decision.
CurveBeam recommends that potential investors consult their professional advisors as an investment in CurveBeam is subject to investment and other known and unknown risks, some of which are beyond the control of CurveBeam or its directors and therefore any investment is considered to be speculative in nature.

Forward looking statements
The information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of CurveBeam's views on future performance or condition. Past performance cannot be relied upon as an indicator of future performance. This presentation contains certain forward-looking statements. The words "forecast", "estimate", "like", "anticipate", "opinion", "should", "could", "may" and other similar expressions are intended to identify future earnings, financial position and performance of CurveBeam. You are cautioned not to place undue reliance on these statements. These forward-looking statements are based on estimates, projections and assumptions made by CurveBeam about circumstances and events that have not yet taken place. Although due care and attention has been used in the preparation of these statements, such forward-looking statements are based on numerous assumptions regarding CurveBeam's present and future business strategies and the political, regulatory and economic environment in which CurveBeam will operate in the future and are subject to change without notice. Statements about market and industry trends, which are based on interpretations of current market conditions, may not be reasonable, and are not guarantees or predictions of future performance.
The actual results or performance of CurveBeam may be materially different from the results or performance expressed or implied by such forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including any of the Limited Parties). In particular, no representation, warranty or assurance (express or implied is given that the occurrence of the events expressed or implied in any forward-looking statement in this presentation will actually occur). Subject to any continuing obligations under applicable law, the Company expressly disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements in this presentation to reflect any change in expectations in relation to any forward-looking statement or any change in events, conditions or circumstances on which any statement is based.

Financial information
All numbers in this presentation are stated in Australian dollars (**A$**) unless stated otherwise.

CurveBeam AI

4C REPORTING DEFINITIONS

- **Purchase order** – a signed purchase order (PO) for a CT scanner (device). The Company considers POs to be the key metric as it reflects actual sales at the time a sale is completed.
- **Receipts from customers** – any cash consideration received from a customer by CurveBeam AI. This can include initial deposits required at the time of an order being placed.
- **Revenue** – Revenue is recognised after the device (e.g., HiRise™) is delivered, installed and training has been completed. Depending on the customer site requirements, there can be several months from a signed purchase order to recognition of revenue. Thus, revenue may not be reflective of sales progress in each period

The Company will report on purchase orders and cash receipts in its Appendix 4C (quarterly) lodgements, while revenue will be reported in the Appendix 4E (full year report) and Appendix 4D (half year report).



CurveBeam AI

4C HIGHLIGHTS

- Foot & Ankle division of Stryker continues to build a **strong sales pipeline**
- Received **4 purchase orders for HiRise**™ devices in Q1 FY24
- A **100% increase** on the prior corresponding period of 2 purchase orders in FY23
- **3 orders with Stryker** – one financed deal
- Directors believe Company from IPO has cash to carry out stated goals for **24 months**
- Established **subsidiary in Germany** – favourable reimbursement
- Advancing **enhanced HiRise (V2)** platform for robotic systems datasets
- Progressing development & FDA file for the bone mineral density **(BMD) module**
- HiRise™ featured - American Orthopedic Foot & Ankle Society' (**AOFAS**) annual meeting
- Listed on ASX - **raised A$25m** in Q1 to support HiRise™ orders – deploying now

CurveBeam AI

AMERICAN ORTHOPEDIC FOOT & ANKLE SOCIETY(AOFAS) ANNUAL MEETING

AOFAS CONFERENCE – 20TH TO 23RD SEPTEMBER 2023

- Management attended conference to see firsthand reactions to HiRise™
- A very positive experience to see the responses from both Stryker representatives, surgeons & group surgeon practice administrators.
- Engaged with numerous prospects to see firsthand the opportunity HiRise™ has and where prospects are in the sales cycle.
- With the IPO completed, and with the investment to support this partnership, we remain very positive on our partnership with Stryker and the continued market adoption of HiRise™.
- The International WBCT Society meeting was well attended & key clinical studies presented HiRise™ and PedCat™.
- Stryker stand activity was supported by CurveBeam AI management and we were introduced to many group practices and hospitals advancing in their interest to acquire a HiRise.

CurveBeam AI

ENHANCED HIRISE™ PROJECT



STRYKER CORPORATION - FOOT & ANKLE DIVISION

- CurveBeam AI is developing enhancements to the HiRise™ platform, including a stronger X-Ray source for larger patients.
- This will enable higher resolution scans of the hip & knee joints required for key surgical systems & patient specific instrumentation (PSI) from multiple providers.
- Targeting scans to be available to vendors in Q2 for validation purposes.
- Targeting validation of datasets for robotics aided surgical systems.
- The Company is targeting commercial launch of the enhanced HiRise™ platform around mid-CY24 to cover robotic knee & hip implants
- The HiRise™ system upgrade is also critical for offering the AI SaaS based CT BMD module on the HiRise™

CurveBeam AI

BMD HIRISE™ MODULE PROGRESS

HiRise™ a change agent



HiRise

- The BMD module is targeting a key annuity stream for sales & profit growth
- The new enhanced HiRise™ platform is needed for the BMD Module
- Patient data will be collected from April 2024 to support the 510(k) submission with devices to be placed at several US sites.
- Filing the submission for a 510(k) clearance of BMD on HiRise™ with the FDA remains on target for mid calendar year 2024.
- FDA 510(k) clearance for BMD on HiRise™ remains on target for late FY25.
- Other FDA submissions continue to progress in their preparation, or FDA review. These include OssView™ and CubeVue Autometrics™.

CurveBeam AI

IN CLOSING

- **Deploying IPO capital** Q1 to support HiRise™ placements for FY24.
- FY24 orders – Company remains very **confident in purchase orders.**
- Directors believe Company from IPO has **cash to carry out stated goals for 24 months.**
- Advancing enhanced HiRise™ platform for **robotic system datasets** to target
  - Expanded support in large practices – Robotic Hip & Knee users in a group practice would like validation from Stryker that HiRise can be used for their robotic systems.
  - Improve diagnostic information of conditions around the hip.
- US FDA filing **bone mineral density (BMD) module** – clearance remains on FY25 target.

CurveBeam AI